Acute coronary syndromes: Biology

Lancet

Volumn 353, Issue SUPPL.2, 1999, Pages 5-9

  Fuster, Valentin ^a   Fayad, Zahi A ^a   Badimon, Juan J ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; LIPOPROTEIN;

ACUTE HEART FAILURE; ANGINA PECTORIS; ATHEROSCLEROTIC PLAQUE; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; THROMBOSIS; VASOCONSTRICTION;

EID: 0033549388     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(99)90234-9     Document Type: Article

References (40)

1. FusterV, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. Parts I and II. N Engl J Med 1992; 326(4): 242-50, 310-88.
2. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. Circulation 1996; 94: 2013-20.
3. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062-1072.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340(2): 115-26.
5. FusterV. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-46.
6. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced type of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-74.
7. Fuster V, Gotto AM, Libby P, Loscalzo J, McGill HC. Matching the intensity of risk factor management with the hazard for coronary disease events. Pathogenesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol 1996; 27: 964-976.
8. Falk E, Shah PK, FusterV. Coronary plaque disruption. Circulation 1995; 92: 657-671.
9. Ambrose JA,Tannenbaum M, Alexpoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12: 56-62.
10. Little WC, Constanninescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78: 1157-66.
11. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophages, and smooth muscle content. Br Heart J 1993; 69: 377-81.
12. Moreno PF, Falk E, Palacios IF, Newell JB, FusterV, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-78.
13. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844.
14. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-69.
15. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism if lesion stabilization. Circulation 1998; 97: 2433-44.
16. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet J, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-53.
17. Burke AP, Farb A, Malcolm GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-81.
18. Fernandez-Ortiz A, Badimon J, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-69.
19. Toschi V, Gallo R, Lettino M, et al. Tissue fractor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-99.
20. Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood composition factor Villa with soluble tissue factor. Nature 1996; 380: 41-46.
21. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells and tissue factor in unstable angina: implications for cell mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090-97.
22. Badimon JJ, Lettino M, ToschiV, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of TFPI on plaque thrombogenicity under flow conditions. Circulation 1999; 14: 1780-87.
23. Giesen PLA, Rauch U, Bohrman B, et al. Blood-borne tissue factor: Another view of thrombosis. Proc Nat Acad Sci USA. 1999; 96: 2311-15.
24. Ridker PM, Glynn RJ, Hennekens CH. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-11.
25. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, Pravastin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-44.
26. Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg Cohort study, 1984 to 1992. Circulation 1999; 99: 237-42.
27. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-60.
28. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354-63.
29. Dangas G, Badimon JJ, Smith DA, et al. Pravastin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33(5): 1294-1304.
30. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research. Circulation 1997; 96: 4095-4103.
31. Maseri A, L'Abbate A, Baroldi G, et al. Coronary vasospasm as a possible cause of myocardial infarction: a conclusion derived from the study of preinfarction angina. N Engl J Med 1978; 299: 1271-1277.
32. Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation 1994; 90: 5-11.
33. Willerson JT, Gobrao P, Fidr J, et al. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205.
34. Theroux P, FusterV. Acute coronary syndromes. Circulation 1998; 97:1 195-1206.
35. Fayad ZA, Fallon JT, Shinnar M, et al. Noninvasive in vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. Circulation 1998; 98: 1541-47.
36. Shinnar M, Fallon JT, Wehrli S, et al. The diagnostic accuracy of ex vivo magnetic resonance imaging for human atherosclerotic plaque characterization. Arterioscler Thromb Vasc Biol (in press).
37. Fayad ZA,Tamana N, Badimon JJ, et al. Magnetic resonance imaging of human atherosclerotic aorta in vivo. Circulation 1998; 98:I-515 (abstr).
38. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation 1998; 97: 946-52.
39. Xu HP, Meisel SR, Ong JM, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinnase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99: 993-98.
40. Fuster V, Fallon JT, Nemerson Y. Coronary thrombosis. Lancet 1996; 348 (suppl): S7-S10.